ASHINGTON — Scott Gottlieb, President Trump’s nominee to lead the Food and Drug Administration, is taking a softer tone than the White House on the issue of a terminally ill patient’s “right to try” medicines still in the early stages of the agency’s approval process.

“If confirmed, I would commit to ensuring FDA has the right policies and processes in place to appropriately balance individual patients’ needs for access to investigational therapies,” Gottlieb wrote to Senator Patty Murray of Washington, the leading Democrat on the committee deciding Wednesday whether to advance his nomination, “while recognizing the importance of maintaining a rigorous clinical trial paradigm for testing investigational products and demonstrating safety and efficacy.”

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • No political or religious figure should have rhe rright to even suggest on the type of drug to be used in the terminally ill patient. Nor he or she shold have the authority to arbitrarely cut funds for research. This in itself demonstrates his or her total ignorance on the matter.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.